Oncimmune (LON:ONC) Stock Price Down 11.8% – Time to Sell?

Oncimmune Holdings plc (LON:ONC) fell 11.8% during trading on Thursday . The company traded as low as GBX 3.40 ($0.04) and last traded at GBX 3.44 ($0.04). 246,795 shares were traded during mid-day trading, a decline of 40% from the average session volume of 408,388 shares. The stock had previously closed at GBX 3.90 ($0.05).

Oncimmune Price Performance

The company has a quick ratio of 0.63, a current ratio of 1.14 and a debt-to-equity ratio of -412.06. The firm has a market capitalization of £2.99 million, a price-to-earnings ratio of 0.30 and a beta of 1.19. The stock’s 50-day moving average price is GBX 11.77 and its 200 day moving average price is GBX 14.52.

Oncimmune (LON:ONC) last announced its earnings results on Monday, February 10th. The company reported GBX (4.72) (($0.06)) earnings per share for the quarter. Oncimmune had a negative return on equity of 2,277.74% and a net margin of 581.63%.

Oncimmune Company Profile

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel.